Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel reagent for the screening of Immunoglobulin A-deficient blood donors.

Vox sanguinis·2026
Same author

Effect of long-term frozen storage on antibodies in blood samples: immunoglobulin, tetanus toxin antibody, and ABO antibody.

Immunohematology·2026
Same author

The national early warning score during unscheduled home visits: retrospective cohort study.

BJGP open·2026
Same author

Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study).

Trials·2026
Same author

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph<sup>+</sup> Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Pediatric blood & cancer·2026
Same author

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

International journal of hematology·2026

Related Experiment Video

Updated: Jun 27, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

[Aspirin resistance].

Shigeki Miyata1, Toshiyuki Miyata, Akiko Kada

  • 1Division of Transfusion Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai Suita-shi, Osaka 565-8565, Japan

Brain and Nerve = Shinkei Kenkyu No Shinpo
|December 17, 2008
PubMed
Summary

Aspirin resistance, where patients do not respond to aspirin therapy, increases cardiovascular event risk. Identifying aspirin non-responders is crucial for personalized antiplatelet treatment strategies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
08:58

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes

Published on: March 3, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
08:58

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes

Published on: March 3, 2023

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Aspirin (acetylsalicylic acid) is a cornerstone for secondary cardiovascular disease prevention by inhibiting platelet activation via cyclooxygenase-1 (COX-1).
  • Despite aspirin's benefits, a significant portion of patients exhibit 'aspirin resistance' (both laboratory and clinical), leading to persistent cardiovascular events.
  • This variability in response necessitates a deeper understanding of aspirin resistance mechanisms and predictive assays.

Purpose of the Study:

  • To investigate the relationship between laboratory measures of aspirin resistance and clinical cardiovascular outcomes.
  • To identify risk factors associated with aspirin resistance, including drug interactions and genetic variations (COX-1 polymorphism).
  • To determine the most effective laboratory assays for predicting cardiovascular events in patients receiving aspirin therapy.

Main Methods:

  • A multicenter, prospective cohort study (ProGEAR study) was conducted.
  • Patients at high risk for cardiovascular events were assessed for platelet reactivity using various laboratory assays.
  • Data on medication adherence, co-administered drugs (e.g., NSAIDs), and COX-1 gene polymorphism were collected.

Main Results:

  • Patients identified as 'laboratory aspirin resistant' demonstrated a significantly higher risk (odds ratio: 3.85) of cardiovascular morbidity compared to sensitive individuals.
  • Preliminary findings suggest that certain laboratory assays may predict clinical outcomes, though further validation is needed.
  • Factors such as non-compliance and concurrent NSAID use are being evaluated as contributors to aspirin resistance.

Conclusions:

  • Aspirin resistance is a clinically relevant phenomenon associated with increased cardiovascular risk.
  • Identifying aspirin non-responders through appropriate laboratory testing can facilitate individualized antiplatelet therapy.
  • Further research is essential to elucidate the precise mechanisms of aspirin resistance and optimize its clinical application for personalized medicine.